menu search

ORIC / Why ORIC Pharmaceuticals Shares Are Plunging Today

Why ORIC Pharmaceuticals Shares Are Plunging Today
ORIC Pharmaceuticals Inc (NASDAQ: ORIC) has decided to discontinue the further development of ORIC-101 after interim analyses from the two Phase 1b studies, wherein ORIC-101 did not demonstrate sufficient clinical activity. The dose-expansion portion of the Phase 1b trial of ORIC-. Read More
Posted: Mar 22 2022, 09:33
Author Name: Benzinga
Views: 111867

ORIC News  

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023

By GlobeNewsWire
October 17, 2023

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023

Company to host a conference call and webcast on Saturday, October 21, 2023, at 9:00 am ET featuring Dr. Alexander Spira to discuss initial data and p more_horizontal

Oric Pharmaceuticals, Inc. (ORIC) Upgraded to Buy: What Does It Mean for the Stock?

By Zacks Investment Research
October 16, 2023

Oric Pharmaceuticals, Inc. (ORIC) Upgraded to Buy: What Does It Mean for the Stock?

Oric Pharmaceuticals, Inc. (ORIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This more_horizontal

ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference

By GlobeNewsWire
September 20, 2023

ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology com more_horizontal

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

By GlobeNewsWire
August 30, 2023

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO and SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focu more_horizontal

Why Shares of Oric Pharmaceuticals Jumped Monday

By The Motley Fool
June 26, 2023

Why Shares of Oric Pharmaceuticals Jumped Monday

Oric Pharmaceuticals specializes in oncology therapies. The company said the private placement will help it fund operations through the end of 2025. more_horizontal

ORIC Pharma: Small Pfizer Deal, Cash, And A Set Of Very Early Stage Assets

By Seeking Alpha
March 15, 2023

ORIC Pharma: Small Pfizer Deal, Cash, And A Set Of Very Early Stage Assets

ORIC has a few early stage cancer targeting molecules. In December, Pfizer made a small $25mn deal with it for the lead asset. more_horizontal

ORIC Pharmaceuticals to Present at the Jefferies Healthcare Conference

By GlobeNewsWire
June 2, 2022

ORIC Pharmaceuticals to Present at the Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology comp more_horizontal

Why ORIC Pharmaceuticals Stock Is Crashing Today

By The Motley Fool
March 22, 2022

Why ORIC Pharmaceuticals Stock Is Crashing Today

The company discontinued development of its lead clinical program. more_horizontal


Search within

Pages Search Results: